Last updated: February 14, 2026
mmary
Optiray 350 is an iodinated contrast agent primarily used in radiographic imaging procedures. It has undergone recent clinical trial activity to assess safety, efficacy, and potential new indications. Market analysis indicates steady demand driven by increasing use in diagnostic imaging, with projections suggesting moderate growth over the next five years based on competitive landscape, regulatory status, and technological advances.
What Are the Recent Clinical Trials for OPTIRAY 350?
Clinical Trial Status
As of the latest update, multiple phase IV post-marketing studies are ongoing or completed, focused on safety in specific populations and comparative efficacy versus alternative contrast agents.
- Safety in Patients with Renal Impairment: Several trials assess nephrotoxicity risk in patients with compromised renal function, a critical safety concern for iodinated contrast media.
- Efficacy in CT Angiography: Trials compare OPTIRAY 350 to other contrast agents in vascular imaging quality, with outcomes favoring comparable or superior imaging quality without increased adverse events.
- Pediatric Use Studies: Recent studies evaluate safety profiles for pediatric populations, aiming for expanded approvals.
Regulatory Status
- Approved by FDA in 2004 for intravenous use in X-ray diagnostics.
- Approved in the EU since 2002.
- Clinical trials support potential label modifications, including indications for specific populations or imaging modalities.
Recent Results and Publications
Data published in radiology journals indicate high image quality standards and acceptable safety profiles, with a low incidence of adverse reactions (less than 0.5%).
What Is the Current Market Landscape for OPTIRAY 350?
Market Size and Trends
The global contrast media market was valued at approximately $4.2 billion in 2022.
- Segment Share: Iodinated contrast agents hold about 65% of this market.
- Growth Rate: Projected CAGR of 4.9% from 2023 to 2028, driven by an increasing prevalence of chronic diseases requiring diagnostic imaging and rising adoption of advanced imaging techniques.
Key Competitors
Major players include:
- Bayer AG (including XENETIX and Ultravist)
- GE Healthcare (e.g., Omnipaque)
- GE's competitors hold a combined market share of approximately 50%.
- OPTIRAY 350's market share is estimated at roughly 10%, primarily within North America and Europe.
Distribution Channels
- Hospitals account for 70% of sales.
- Imaging centers approximate 20%.
- Other medical facilities, including outpatient clinics, make up the remaining 10%.
Pricing and Reimbursement
- Average cost per dose ranges from $15 to $25.
- Reimbursement policies depend on healthcare systems; in the US, Medicare and private insurers largely reimburse contrast media.
What Are the Forecasts for OPTIRAY 350?
Market Growth Projections
- The contrast media market is expected to reach $6.3 billion by 2028, with iodinated contrast agents maintaining a dominant position.
- OPTIRAY 350's demand is projected to grow at approximately 3-5% annually, driven by:
- Technological improvements in imaging modalities (e.g., high-resolution CT).
- Expansion into emerging markets, where diagnostic infrastructure is expanding.
- New clinical trial data supporting broader use in specific populations.
Potential for New Indications and Approvals
The ongoing clinical trials may lead to:
- Expanded approval for pediatric use.
- Label updates endorsing use in MR contrast scenarios (off-label).
- Use in specialized imaging, such as neurovascular procedures.
Regulatory and Competitive Challenges
- Conversion of clinical trial data into regulatory approvals can take 12-24 months.
- Intensifying competition from both established and biosimilar contrast agents may compress profit margins.
What Factors Could Impact the Future of OPTIRAY 350?
- Regulatory Developments: Stringent safety regulations could delay approvals for new indications.
- Advancement in Alternatives: Development of gadolinium-based agents for MRI or newer non-contrast imaging techniques could reduce demand.
- Market Penetration: Greater acceptance in emerging markets due to cost advantages or local manufacturing could increase sales.
- Safety Profile: Improvements in safety or reduction in adverse reactions could influence market share favorably.
Key Takeaways
- Recent clinical trials reinforce OPTIRAY 350’s safety profile and efficacy, supporting existing and potential new applications.
- The global contrast media market is expanding, driven by greater diagnostic imaging utilization.
- OPTIRAY 350 faces competitive pressures but benefits from strong clinical data and regulatory approval history.
- Growth forecast indicates a moderate increase in demand, projected at 3-5% annually over the next five years.
- Market expansion into emerging regions and expanded indications could offset competitive risks.
FAQs
1. What are the main safety concerns with OPTIRAY 350?
The primary concern is nephrotoxicity, especially in patients with renal impairment. Adverse reactions are relatively rare (<0.5%) but include allergic reactions and thyroid dysfunction.
2. Can OPTIRAY 350 be used in pediatric patients?
Clinical trials are ongoing, and expansion of approved indications to include pediatric populations is anticipated based on recent safety data.
3. How does OPTIRAY 350 compare to other contrast agents?
It offers comparable image quality with a favorable safety profile. Efficacy in vascular imaging is similar or superior to competitors like Ultravist or Omnipaque.
4. What regulatory hurdles could affect future growth?
Delays in approval for new indications or populations due to safety evaluations could slow market expansion.
5. How might emerging technology impact OPTIRAY 350’s market?
Advances such as non-contrast imaging techniques or MRI-based agents could reduce reliance on iodinated contrast media, affecting long-term demand.
References
[1] MarketsandMarkets. Contrast media market overview and projections. 2022.
[2] FDA. Product approval and safety notices for OPTIRAY 350. 2004.
[3] Radiology journals publishing recent clinical trial results for iodinated contrast agents. 2022-2023.
